
Marianne Jansson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/735238/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity. Science, 2000, 287, 860-864.	12.6	1,042
2	Tuberculosis and HIV Co-Infection. PLoS Pathogens, 2012, 8, e1002464.	4.7	549
3	T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. PLoS Pathogens, 2014, 10, e1004251.	4.7	273
4	Cutting Edge: Attenuated Experimental Autoimmune Encephalomyelitis in Eta-1/Osteopontin-Deficient Mice. Journal of Immunology, 2002, 168, 2096-2099.	0.8	169
5	T-bet-dependent expression of osteopontin contributes to T cell polarization. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17101-17106.	7.1	138
6	Microbial Translocation Correlates with the Severity of Both HIVâ€1 and HIVâ€2 Infections. Journal of Infectious Diseases, 2010, 201, 1150-1154.	4.0	99
7	Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. New England Journal of Medicine, 2012, 367, 224-232.	27.0	94
8	Coevolution of RANTES Sensitivity and Mode of CCR5 Receptor Use by Human Immunodeficiency Virus Type 1 of the R5 Phenotype. Journal of Virology, 2004, 78, 11807-11815.	3.4	81
9	Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. Journal of General Virology, 2005, 86, 3385-3396.	2.9	69
10	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	2.5	63
11	Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV,the, 2019, 6, e25-e31.	4.7	57
12	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology, 2005, 86, 2859-2869.	2.9	56
13	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology, 2008, 379, 125-134.	2.4	45
14	Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1. Journal of Virology, 2012, 86, 961-971.	3.4	39
15	Length Variation of Glycoprotein 120 V2 Region in Relation to Biological Phenotypes and Coreceptor Usage of Primary HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 2001, 17, 1405-1414.	1.1	33
16	Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. Journal of Infectious Diseases, 2014, 209, 721-728.	4.0	33
17	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-957.	2.2	32
18	Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants. Aids, 1997, 11, 1709-1717.	2.2	31

MARIANNE JANSSON

#	Article	IF	CITATIONS
19	CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection. Aids, 2016, 30, 2415-2426.	2.2	30
20	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	4.7	30
21	Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS ONE, 2018, 13, e0193589.	2.5	29
22	Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections. Aids, 2016, 30, 1713-1722.	2.2	27
23	Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis and Rheumatism, 2004, 50, 2685-2694.	6.7	25
24	Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count. PLoS ONE, 2015, 10, e0144292.	2.5	24
25	HIV-2 as a model to identify a functional HIV cure. AIDS Research and Therapy, 2019, 16, 24.	1.7	24
26	Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine, 2009, 46, 325-331.	3.2	23
27	Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology, 2008, 5, 28.	2.0	21
28	CCR5 or CXCR4 Is Required for Efficient Infection of Peripheral Blood Mononuclear Cells by Promiscuous Human Immunodeficiency Virus Type 2 Primary Isolates. AIDS Research and Human Retroviruses, 2002, 18, 193-200.	1.1	20
29	Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge. PLoS ONE, 2011, 6, e20135.	2.5	16
30	Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques. Journal of Virology, 2011, 85, 6442-6452.	3.4	16
31	Tuberculosis Infection in Women of Reproductive Age: A Cross-sectional Study at Antenatal Care Clinics in an Ethiopian City. Clinical Infectious Diseases, 2021, 73, 203-210.	5.8	16
32	Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid Isolates. AIDS Research and Human Retroviruses, 2009, 25, 1297-1305.	1.1	13
33	Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine, 2009, 28, 270-278.	3.8	13
34	Effect of HIV-2 infection on HIV-1 disease progression and mortality. Aids, 2014, 28, 614-615.	2.2	13
35	Plasma Profiles of Inflammatory Markers Associated With Active Tuberculosis in Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Positive Individuals. Open Forum Infectious Diseases, 2019, 6, ofz015.	0.9	13
36	Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model. PLoS ONE, 2013, 8, e74552.	2.5	12

MARIANNE JANSSON

#	Article	IF	CITATIONS
37	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. Journal of Virology, 2016, 90, 9855-9861.	3.4	12
38	Effect of Complement on HIV-2 Plasma Antiviral Activity Is Intratype Specific and Potent. Journal of Virology, 2013, 87, 273-281.	3.4	11
39	Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4+ T Cells. PLoS ONE, 2014, 9, e88195.	2.5	11
40	Prevalence of HIV-1 pretreatment drug resistance among treatment naÃ⁻ve pregnant women in Bissau, Guinea Bissau. PLoS ONE, 2018, 13, e0206406.	2.5	11
41	Frequent Intratype Neutralization by Plasma Immunoglobulin A Identified in HIV Type 2 Infection. AIDS Research and Human Retroviruses, 2013, 29, 470-478.	1.1	10
42	Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines, 2013, 1, 305-327.	4.4	10
43	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-57.	2.2	9
44	The Role of Virologic and Immunologic Factors in Motherâ€ŧoâ€Child Transmission of HIVâ€1. American Journal of Reproductive Immunology, 1997, 38, 197-200.	1.2	8
45	Mycobacteriaâ€infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate <scp>HIV</scp> transinfection. European Journal of Immunology, 2012, 42, 1192-1202.	2.9	8
46	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. AIDS Research and Therapy, 2020, 17, 33.	1.7	8
47	Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein–Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2–Infected Individuals. Journal of Infectious Diseases, 2019, 219, 1749-1754.	4.0	7
48	Low Postseroconversion CD4 + T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection. MBio, 2019, 10, .	4.1	7
49	Alternative biomarkers for classification of latent tuberculosis infection status in pregnant women with borderline Quantiferon plus results. Tuberculosis, 2020, 124, 101984.	1.9	7
50	The Evolution of HIV-1 Interactions with Coreceptors and Mannose C-Type Lectin Receptors. Progress in Molecular Biology and Translational Science, 2015, 129, 109-140.	1.7	6
51	Longitudinal Mycobacterium tuberculosis-Specific Interferon Gamma Responses in Ethiopian HIV-Negative Women during Pregnancy and Postpartum. Journal of Clinical Microbiology, 2021, 59, e0086821.	3.9	6
52	Suppression of HIV Replication In Vitro by CpG and CpG Conjugated to the Non Toxic B Subunit of Cholera Toxin. Current HIV Research, 2008, 6, 230-238.	0.5	5
53	Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals. Frontiers in Immunology, 2021, 12, 744530.	4.8	5
54	Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. BMC Infectious Diseases, 2014, 14, 472.	2.9	4

MARIANNE JANSSON

P			· · · · · · · · · · · · · · · · · · ·
	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. ournal of Immunology, 2014, 192, 5802-5812.	0.8	4
	New insights are game-changers in HIV-2 disease management – Authors' reply. Lancet HIV,the, 2019, 6, 214-e215.	4.7	4
57 C	Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high terebrospinal fluid viral load. Aids, 2012, 26, 1739-1744.	2.2	3
	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Human Vaccines and Immunotherapeutics, 2013, 9, 2103-2110.	3.3	3
59 C	Cocirculation of Several Similar But Unique HIV-1 Recombinant Forms in Guinea-Bissau Revealed by Near Full-Length Genomic Sequencing. AIDS Research and Human Retroviruses, 2015, 31, 938-945.	1.1	3
	uberculosis infection and stillbirth in Ethiopia—A prospective cohort study. PLoS ONE, 2022, 17, 20261972.	2.5	3
	Kynurenine/tryptophan ratio for detection of active tuberculosis in adults with HIV prior to Intiretroviral therapy. Aids, 2022, 36, 1245-1253.	2.2	3
62 Ir B	nterferon Alpha-Inducible Protein 27 Expression Is Linked to Disease Severity in Chronic Infection of 3oth HIV-1 and HIV-2. Frontiers in Virology, 0, 2, .	1.4	3
63 R	R5 human immunodeficiency virus type 1 with efficient DC-SIGN use is not selected for early after birth n vertically infected children. Journal of General Virology, 2013, 94, 767-773.	2.9	2
	Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e79-e82.	2.1	2
	Dendritic Cell Response to HIV-1 Is Controlled by Differentiation Programs in the Cells and Strain-Specific Properties of the Virus. Frontiers in Immunology, 2017, 8, 244.	4.8	2
66 R	Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. Vaccines, 2021, 9, 260.	4.4	2
67 Ç	Quantification of HIV-2 DNA in Whole Blood. Bio-protocol, 2019, 9, e3404.	0.4	1
68 O	Expression of MicroRNAs Is Dysregulated by HIV While Mycobacterium tuberculosis Drives Alterations of Small Nucleolar RNAs in HIV Positive Adults With Active Tuberculosis. Frontiers in Microbiology, 2021, 12, 808250.	3.5	1
	Coreceptor Usage of Primary HIV Type 1 Isolates Obtained from Different Lymph Node Subsets. AIDS Research and Human Retroviruses, 2005, 21, 1003-1010.	1.1	0
70 R	Reply to Redd et al. Journal of Infectious Diseases, 2011, 203, 746-746.	4.0	0
71 H	HV-2 Infection: The Role of Immune Activation in Pathogenesis. , 2013, , 1-8.		0

HIV-2 Infection: The Role of Immune Activation in Pathogenesis. , 2018, , 956-962.

#	Article	IF	CITATIONS
73	HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs. International Journal of Molecular Sciences, 2022, 23, 4766.	4.1	0